Concomitant pharmaceutical agents and use thereof
A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and (b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof.
1. A method for treating hyperglycemia, diabetes, an insulin resistant glucose metabolism disorder, an impaired glucose tolerance condition, or an impaired fasting plasma glucose condition in a warm-blooded mammal, which comprises simultaneously or separately administering
(a) 1-50 mg of 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine 2.5 hydrobromide, or a hydrate thereof, and
(b) an antidiabetic drug selected from the group consisting of (i) a sulfonylurea agent, (ii) a glitazone, (iii) a biguanide, and (iv) an alpha-glucosidase inhibitor, or a pharmaceutically acceptable salt thereof,
to a warm-blooded mammal, thereby treating hyperglycemia, diabetes, an insulin resistant glucose metabolism disorder, an impaired glucose tolerance condition, or an impaired fasting plasma glucose condition in the warm-blooded mammal.
2. The method of claim 1 , wherein the antidiabetic drug is at least one agent selected from the group consisting of metformin and an α-glucosidase inhibitor, and pharmaceutically acceptable salts thereof.
3. The method of claim 1 , wherein the antidiabetic drug is selected from the group consisting of glimepiride, glipizide, and glyburide, or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the antidiabetic drug is selected from the group consisting of pioglitazone, troglitazone, and rosiglitazone, or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the antidiabetic drug is metformin or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the antidiabetic drug is selected from the group consisting of acarbose, voglibose, and miglitol, or a pharmaceutically acceptable salt thereof.
7. A method of decreasing plasma glucose level in a warm-blooded mammal without causing insulin secretion, which comprises simultaneously or separately administering
(a) 1-50 mg of 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine 2.5 hydrobromide, or a hydrate thereof, and
(b) an alpha-glucosidase inhibitor or a pharmaceutically acceptable salt thereof, to a warm-blooded mammal, thereby decreasing the plasma glucose level in the warm-blooded mammal.